<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790113</url>
  </required_header>
  <id_info>
    <org_study_id>Arthrex 003</org_study_id>
    <nct_id>NCT01790113</nct_id>
  </id_info>
  <brief_title>Arthrex Eclipse™ Shoulder Prosthesis</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of&#xD;
      Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a&#xD;
      degenerative joint disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority of the Arthrex Eclipse™ Shoulder&#xD;
      Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative&#xD;
      joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority&#xD;
      in terms of safety and effectiveness will be measured by a 2 year composite clinical success&#xD;
      (CCS) that requires functional improvement, radiographic success, absence of reoperations and&#xD;
      revision, and lack of serious device-related adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Eclipse Shoulder System received 510(k) clearance on July 26, 2019.&#xD;
  </why_stopped>
  <start_date type="Actual">February 4, 2013</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Clinical Success</measure>
    <time_frame>2 year</time_frame>
    <description>To be considered a success, the eclipse subject must meet the following composite clinical success criteria:&#xD;
An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is &gt; or = to 10 and a final Adjusted Constant Score &gt; or + to 54.&#xD;
Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month time-point), glenoid migration/subsidence (relative to the 3 month time-point), device disassembly or fracture, and/or periprosthetic fracture, as described in the radiographic protocol.&#xD;
No reoperation, removal or modification of any study component up to the subject's completion of the study.&#xD;
No serious device-related complications up to the subject's completion of the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Univer™ II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Univers™ II Total Shoulder Replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eclipse™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eclipse™ Total Shoulder Replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Univers™</intervention_name>
    <description>Control</description>
    <arm_group_label>Univer™ II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eclipse™ Total Shoulder Replacement</intervention_name>
    <description>Investigational</description>
    <arm_group_label>Eclipse™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is &gt; 21 years of age&#xD;
&#xD;
          -  The subject has continued symptoms in target shoulder despite at least 3 months of&#xD;
             other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid&#xD;
             injections)&#xD;
&#xD;
          -  The subject has a diagnosis in the target shoulder of one or more of the following:&#xD;
&#xD;
        osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.&#xD;
&#xD;
          -  The subject presents with pain and functional impairment in the index shoulder,&#xD;
             measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will&#xD;
             be calculated from the raw Constant Score to establish patient eligibility.&#xD;
&#xD;
          -  The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or&#xD;
             Univers™ II Shoulder Prosthesis.&#xD;
&#xD;
          -  The subject must be physically and mentally willing and able to comply with all study&#xD;
             procedures (including follow-up visits and radiographic assessments) until the&#xD;
             conclusion of the study.&#xD;
&#xD;
          -  The subject has been informed of the nature of the study and provided written consent&#xD;
             as approved by the sites local Institutional Review Board or Ethic Review Board.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular&#xD;
             Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff&#xD;
             Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid&#xD;
             replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid&#xD;
             involvement.&#xD;
&#xD;
          -  The subject has immature bone as defined by the absence of cancellous bone patterning,&#xD;
             a mature, thick cortex, and stress lines within the cancellous bone.&#xD;
&#xD;
          -  The subject has obvious defects in bone quality, such as cysts or lesions, in the&#xD;
             humeral head of the target shoulder, as demonstrated by radiographic evaluation.&#xD;
&#xD;
          -  The subject has a target shoulder a rotator cuff that is not intact and not&#xD;
             reconstructible.&#xD;
&#xD;
          -  The subject has Irreducible 3- and 4- part proximal humeral fractures of the target&#xD;
             shoulder.&#xD;
&#xD;
          -  The subject has documented history of foreign-body sensitivity.&#xD;
&#xD;
          -  Subject with positive pregnancy test, or lactating, or intends to become pregnant&#xD;
             during treatment period&#xD;
&#xD;
          -  The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive&#xD;
             Disorder as defined by DSM IV.&#xD;
&#xD;
          -  The subject is skeletally immature demonstrated radiographically by incomplete closure&#xD;
             of proximal humeral epiphyses.&#xD;
&#xD;
          -  The subject is at high risk for poor healing or confounding outcomes [(i.e.:&#xD;
             clinically significant renal, hepatic, cardiac hematologic disease or endocrine&#xD;
             disease)]&#xD;
&#xD;
          -  The subject is on immune-stimulating or immunosuppressive agents&#xD;
&#xD;
          -  The subject has co-morbidity that reduces life expectancy &lt; 36 month.&#xD;
&#xD;
          -  The subject seeking or receiving workman's compensation for shoulder injury,&#xD;
&#xD;
          -  The subject is &gt; 350 lbs.&#xD;
&#xD;
          -  The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than&#xD;
             50 lbs.)&#xD;
&#xD;
          -  The subject has had surgery in the affected shoulder in the last 12 months (with the&#xD;
             exception of diagnostic arthroscopy without reconstruction or repair procedures)&#xD;
&#xD;
          -  The subject is engaged in active sports participation. (e.g. weight lifting involving&#xD;
             upper extremities or involved in contact sports)&#xD;
&#xD;
          -  The subject is taking medications known to potentially interfere with bone/soft tissue&#xD;
             healing (e.g. steroids with the exception of topical and/or inhalers)&#xD;
&#xD;
          -  The subject is a prisoners or wards of the state&#xD;
&#xD;
          -  The subject has a history of alcohol and/or substance abuse as defined by DSM IV&#xD;
             (Diagnostic and Statistical Manual Diploma in Social Medicine)&#xD;
&#xD;
          -  The subject has an active or chronic infection, either systemic or local.&#xD;
&#xD;
          -  The subject has pathologic fractures of the affected shoulder&#xD;
&#xD;
          -  The subject has acute trauma of the affected shoulder&#xD;
&#xD;
          -  The subject has osteoporosis defined as a bone density T score of &lt; or = -2.5. (A&#xD;
             screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk&#xD;
             Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to&#xD;
             screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral&#xD;
             density measurement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Hirschberg</last_name>
    <role>Study Director</role>
    <affiliation>Arthrex, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Research</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedics Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Orthopaedics</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Orthopaedics at Rush</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis and Badenhausen Orthopedics PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Orthopaedics Associates, P.A.</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excelsior Orthopedics</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Universtiy</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adena Health System</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute at Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Oregon Orthopedics</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics)</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>December 13, 2019</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT01790113/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In February 2013, the first subject was enrolled in the study and the last subject was enrolled in August 2018. Subjects were enrolled at both academic and private study sites.</recruitment_details>
      <pre_assignment_details>The treated population was 303 subject, with 224 Eclipse subjects and 79 Univers II subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Univers™ II</title>
          <description>Univers™ II Total Shoulder Replacement&#xD;
Univers™: Control</description>
        </group>
        <group group_id="P2">
          <title>Eclipse™</title>
          <description>Eclipse™ Total Shoulder Replacement&#xD;
Eclipse™ Total Shoulder Replacement: Investigational</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study ended due to FDA clearance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>303 were treated (224 Eclipse and 79 Univers II).</population>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator: Univer II</title>
          <description>Univer II Total Shoulder Replacement</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Eclipse</title>
          <description>Eclipse Total shoulder Replacement</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="23" upper_limit="85"/>
                    <measurement group_id="B2" value="66" lower_limit="37" upper_limit="86"/>
                    <measurement group_id="B3" value="66" lower_limit="23" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Clinical Success</title>
        <description>To be considered a success, the eclipse subject must meet the following composite clinical success criteria:&#xD;
An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is &gt; or = to 10 and a final Adjusted Constant Score &gt; or + to 54.&#xD;
Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month time-point), glenoid migration/subsidence (relative to the 3 month time-point), device disassembly or fracture, and/or periprosthetic fracture, as described in the radiographic protocol.&#xD;
No reoperation, removal or modification of any study component up to the subject's completion of the study.&#xD;
No serious device-related complications up to the subject's completion of the study.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Univer™ II</title>
            <description>Univers™ II Total Shoulder Replacement&#xD;
Univers™: Control</description>
          </group>
          <group group_id="O2">
            <title>Eclipse™</title>
            <description>Eclipse™ Total Shoulder Replacement&#xD;
Eclipse™ Total Shoulder Replacement: Investigational</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Clinical Success</title>
          <description>To be considered a success, the eclipse subject must meet the following composite clinical success criteria:&#xD;
An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is &gt; or = to 10 and a final Adjusted Constant Score &gt; or + to 54.&#xD;
Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month time-point), glenoid migration/subsidence (relative to the 3 month time-point), device disassembly or fracture, and/or periprosthetic fracture, as described in the radiographic protocol.&#xD;
No reoperation, removal or modification of any study component up to the subject's completion of the study.&#xD;
No serious device-related complications up to the subject's completion of the study.</description>
          <units>percentage of success rate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator: Univer II</title>
          <description>Univer II Total Shoulder Replacement</description>
        </group>
        <group group_id="E2">
          <title>Experimental: Eclipse</title>
          <description>Eclipse Total shoulder Replacement</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abnormal Blood levels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Blood Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cardia Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>gastric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non device /procedure related SAE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Device -Related SAE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Procedure Related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs Manager</name_or_title>
      <organization>Arthrex</organization>
      <phone>2392161894</phone>
      <email>melissa.hirschberg@arthrex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

